Home/Filings/4/0001628280-25-008262
4//SEC Filing

Mottola Frank 4

Accession 0001628280-25-008262

CIK 0001356576other

Filed

Feb 25, 7:00 PM ET

Accepted

Feb 26, 5:56 PM ET

Size

13.6 KB

Accession

0001628280-25-008262

Insider Transaction Report

Form 4
Period: 2025-02-26
Mottola Frank
SVP, Quality, GMP, Ops, IT
Transactions
  • Exercise/Conversion

    Performance Share Units

    2025-02-262,0100 total
    Exercise: $0.00Common Stock (2,010 underlying)
  • Exercise/Conversion

    Performance Share Units

    2025-02-263,7500 total
    Exercise: $0.00Common Stock (3,750 underlying)
  • Exercise/Conversion

    Common Stock

    2025-02-26+2,01014,909 total
  • Exercise/Conversion

    Common Stock

    2025-02-26+3,75017,683 total
  • Tax Payment

    Common Stock

    2025-02-26$39.48/sh976$38,53213,933 total
  • Tax Payment

    Common Stock

    2025-02-26$39.48/sh1,909$75,36715,774 total
Footnotes (3)
  • [F1]Represents the number of shares of common stock withheld by the Company to satisfy tax withholding requirements in connection with the vesting of Performance Share Units.
  • [F2]On February 22, 2022, the Reporting Person was awarded Performance Share Units, a portion of which vested upon the achievement of individual performance objectives within a defined performance period, which objectives were established on May 3, 2022.
  • [F3]On February 23, 2023, the Reporting Person was awarded Performance Share Units, a portion of which vested upon the achievement of individual performance objectives within a defined performance period, which objectives were established on June 12, 2023.

Issuer

SUPERNUS PHARMACEUTICALS, INC.

CIK 0001356576

Entity typeother

Related Parties

1
  • filerCIK 0001804567

Filing Metadata

Form type
4
Filed
Feb 25, 7:00 PM ET
Accepted
Feb 26, 5:56 PM ET
Size
13.6 KB